Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. develops and commercializes cell and gene therapies for serious diseases. Its updates center on ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa, including qualified treatment center activations, commercial launch activity, manufacturing and patient-treatment progress.
Company news also covers financial results, corporate progress, employee inducement equity awards under Nasdaq rules, board and committee changes, and development work involving AAV-based gene therapies and next-generation AAV capsids for ophthalmic and other serious diseases.
Abeona Therapeutics (ABEO) announced key developments in its clinical programs, including the first patient treated in the Phase 3 VIITAL™ study for EB-101, targeting recessive dystrophic epidermolysis bullosa. The company also reported positive interim data on gene therapies for MPS IIIA and MPS IIIB at WORLDSymposium™, highlighting improvements in neurocognitive skills and disease-specific biomarkers. Financially, Abeona reported a net loss of $0.52 per share for Q1 2020, influenced by a $32.9 million impairment charge. The company appointed new executives to strengthen its leadership team.